Home › Funds › Paradigm Biocapital Advisors LP › ERAS

Paradigm Biocapital Advisors LP position in ERAS

ERASCA INC · Health Care

Paradigm Biocapital Advisors LP reported holding 7,998,257 shares of ERAS (ERASCA INC) in its Q3 2026 13F filing — a position valued at US$117.3M, representing 2.33% of its reported portfolio and ranking #14 among its reported holdings. Paradigm Biocapital Advisors LP has disclosed ERAS holdings in 10 of the last 10 reported quarters, going back to Q2 2024.

Latest position (Q3 2026)8.00M sh
Reported value held$117.25M
Portfolio Weight2.33%
First reportedQ2 2024
Last changeReduce
Updated2026-11-16

Last updated: 2026-11-16 · Source: SEC EDGAR Form 13F-HR

How Paradigm Biocapital Advisors LP's ERAS position evolved

Paradigm Biocapital Advisors LP first disclosed a stake in ERAS in Q2 2024 at 7,250,000 shares (US$17.1M). The position peaked in Q2 2026 at 9,550,000 shares, worth US$175.0M. Across 10 filings, Paradigm Biocapital Advisors LP increased the stake 5 time(s), trimmed it 3 time(s) and left it unchanged 1 time(s). The most recent filing (Q3 2026) shows 7,998,257 shares valued at US$117.3M — a reduction of -1,551,743 shares quarter over quarter.. Notable position changes include a 47% increase in Q3 2024 (shares fell 8% over the following quarter), a 27% trim in Q1 2026 (shares rose 13% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q2 2024 7.25M $17.11M New
Q3 2024 10.67M $29.12M Add
Q4 2024 10.75M $26.99M Add
Q1 2025 10.80M $14.80M Hold
Q2 2025 11.91M $15.12M Add
Q3 2025 13.56M $29.56M Add
Q4 2025 14.16M $52.67M Add
Q1 2026 10.39M $168.15M Reduce
Q2 2026 9.55M $174.96M Reduce
Q3 2026 8.00M $117.25M Reduce

Dots on the line are colored by change type; missing quarters mean no position was reported.

About ERAS and 13F data

ERAS (ERASCA INC) is a Health Care company. 73 other funds we track also report a position in ERAS — the largest reported positions include Frazier Life Sciences Management, L.P. (US$457.5M), RTW INVESTMENTS, LP (US$329.1M), Venrock Adviser, LLC (US$327.8M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding ERAS

All ERAS fund holders →

FAQ

How long has Paradigm Biocapital Advisors LP held ERAS?

Paradigm Biocapital Advisors LP has disclosed ERAS holdings in 10 of the last 10 reported quarters, going back to Q2 2024.

What is Paradigm Biocapital Advisors LP's current position in ERAS?

As of Q3 2026, Paradigm Biocapital Advisors LP holds 8.00M shares of ERAS (ERASCA INC), valued at $117.25M, representing 2.33% of its reported portfolio and ranking #14.

Has Paradigm Biocapital Advisors LP been buying or selling ERAS?

In the latest 13F filing (Q3 2026), Paradigm Biocapital Advisors LP reduced its position in ERAS. The position peaked in Q2 2026 at 9.55M shares.

Which other funds hold ERAS?

Other major institutional holders of ERAS include Frazier Life Sciences Management, L.P., RTW INVESTMENTS, LP, Venrock Adviser, LLC, among 73 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.